1998
DOI: 10.1097/00008571-199810000-00011
|View full text |Cite
|
Sign up to set email alerts
|

Predisposition towards urolithiasis associated with the NQ01 null-allele

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2000
2000
2019
2019

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(6 citation statements)
references
References 0 publications
0
6
0
Order By: Relevance
“…Individuals carrying both mutated genomic alleles are completely deficient in NQO1 activity, whereas heterozygous individuals have intermediate NQO1 activity compared with normal individuals [29,30]. Approximately 2–4% individuals are homozygous and 20–25% are heterozygous for this mutation [31,32]. The current studies suggest that human individuals that carry NQO1P187S homo- or heterozygous mutation are susceptible to develop PBS and are a subject of future investigation.…”
Section: Discussionmentioning
confidence: 96%
“…Individuals carrying both mutated genomic alleles are completely deficient in NQO1 activity, whereas heterozygous individuals have intermediate NQO1 activity compared with normal individuals [29,30]. Approximately 2–4% individuals are homozygous and 20–25% are heterozygous for this mutation [31,32]. The current studies suggest that human individuals that carry NQO1P187S homo- or heterozygous mutation are susceptible to develop PBS and are a subject of future investigation.…”
Section: Discussionmentioning
confidence: 96%
“…NQO1*2 homozygosity appears to be correlated with an increased risk of renal cell cancer and urothelial cell carcinoma (Table 3), with OR values of 1.7 and 3.6, respectively 36 ; there is also a heightened predisposition toward urolithiasis (kidney stones) with an OR of 2.97. 37 For patients with renal cell carcinoma and urothelial carcinoma, 36 all 95% confidence intervals in this study contained the value of 1.0, however, except for the renal cell carcinoma NQO1*1/*2 heterozygotes compared with controls (Table 3). Again, a loss in power is likely due to the small study population (renal cell carcinoma patients, N ϭ 131; urothelial carcinoma patients, N ϭ 99; and controls, N ϭ 260).…”
Section: Interactions Nqo1*2 Allele and Other Diseasesmentioning
confidence: 57%
“…The distribution of the NQO1*2 allele in urolithiasis patient populations 37 was significantly higher, based on Mantel-Haenzel chi-squared analysis (P ϭ 0.003). Heterozygotes experienced a 1.8-fold increased risk of urolithiasis (95% CI, 1.17-2.86).…”
Section: Interactions Nqo1*2 Allele and Other Diseasesmentioning
confidence: 98%
“…A single nucleotide polymorphism (SNP) C to T at position 609 (rs1800566) in the NQO1 coding region (replacing proline with serine at codon 187) leads to lower enzyme activity and has been shown to be associated with increased risk of myeloid leukemia and bladder carcinoma[12,13]. Myeloperoxidase ( MPO ) is an endogenous oxidant enzyme that generates reactive oxygen species (ROS).…”
Section: Introductionmentioning
confidence: 99%